We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Convatec Group Plc | CTEC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -1.60 | -0.56% | 285.00 | 16:35:16 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 285.60 | 283.80 | 288.80 | 285.00 | 286.60 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| 06/03/2024 | Final | GBP | 0.03517 | 25/04/2024 | 26/04/2024 | 23/05/2024 |
| 02/08/2023 | Interim | GBP | 0.0138 | 17/08/2023 | 18/08/2023 | 28/09/2023 |
| 04/08/2022 | Interim | GBP | 0.0141 | 25/08/2022 | 26/08/2022 | 06/10/2022 |
| 30/07/2021 | Interim | GBP | 0.01229 | 02/09/2021 | 03/09/2021 | 14/10/2021 |
| 05/03/2021 | Final | GBP | 0.02845 | 01/04/2021 | 06/04/2021 | 13/05/2021 |
| 06/08/2020 | Interim | GBP | 0.013057 | 03/09/2020 | 04/09/2020 | 15/10/2020 |
| 28/02/2020 | Final | GBP | 0.030948 | 02/04/2020 | 03/04/2020 | 14/05/2020 |
| Interim | GBP | 0.01404 | 04/09/2019 | 06/09/2019 | 17/10/2019 |
| Top Posts |
|---|
Posted at 12/5/2022 17:38 by km18 ConvaTec Group plc issued an AGM trading update for the four months ended 30 April 2022 this morning. Group revenue increased by 4.1% on a reported basis, up 7.5% on a constant currency basis and up 6.0% on an organic basis. ConvaTec has made a good start to the year with good underlying growth in each of its four categories in line with expectations. ConvaTec also announced that it will be withdrawing from its hospital care activities and related industrial sales during the remainder of 2022. These low margin activities being exited generated $ 101 m of revenue in 2021. Given this phased exit of the hospital care and related industrial sales products, reported revenue in 2022 is expected to be approximately $ 20-30 m lower than 2021 and adjusted EBIT is expected to reduce by $3-5m. There is also expected to be a one-off adjusted P&L charge of approximately $55m, which will be incurred in 2022, and a cash cost of approximately $25m arising mainly in 2022. FY22 guidance is unchanged, management expect organic revenue growth of between 4.0% and 5.5% and a constant currency EBIT margin of at least 18%. Valuation is average, profitability is decent, growth relatively modest. The share price also lacks some momentum. CTEC is a share to monitor for now.......from WealthOracleAM |
Posted at 16/3/2021 20:46 by thewheeliedealer Hi all,My mate Peter @Conkers3 and myself did a ‘Twin Petes Investing’ Podcast last week and part of our discussion includes CTEC which we both see as a decent and solid Long-Term Hold kind of Stock. As always we also chatted about loads of other Stocks and Ideas for research and a fair bit of educational stuff with regards to Investing and Portfolio Management. Specific topics in this one include the risks of anonymous Twitter Accounts and the devious tricks the ‘owners’ get up to, and we give examples of our own Trades and how we have Scaled in and Scaled out etc. Anyway, if you use Youtube, Apple, Audioboom, Overcast, Google+ or Spotify you can find it under the 'Conkers Corner' Channel (you want Podcast TPI 44) and you can find it on Soundcloud at the link below. I hope you enjoy it and find it useful, we try to keep them light and they are totally unscripted, with the intent being that it is like you are eavesdropping on us having a chat down the local boozer (we can dream !!). Cheers, WD @wheeliedealer |
Posted at 23/12/2020 12:15 by robow CTEC is one of Shares magazine top picks for 2021. In brief - the business is looking healthier after rectifing earlier mistakes and earnings growth is back on the menu |
Posted at 31/5/2020 14:12 by doubleorquits Indeed, although I feel it may lose out to Kingfisher in the final furlong. The top four to replace the losers highlighted in The Observer are AVST,GVC,HSV and KGF at the moment although it is close between the latter and CTEC (I think all the others are safer bets). Review actually takes place at the close on Tuesday and changes become confirmed on Monday 22nd June.The following site is an excellent reference point for this: NB: All five might go in if ITV loses a bit more ground in the next three days. |
Posted at 31/5/2020 13:56 by hootstox Getting some coverage about FTSE100 changeover, CTEC could move up on Fridayhttps://www.th |
Posted at 28/7/2019 13:27 by robow CTEC gets a mention in todays TimesConvatec could be a comfort in old age. 'there could be rewards ahead...BUY' |
Posted at 02/4/2019 08:39 by robow from Citywire 26 Mar 19AJ Bell: Convatec in need of a shake-up A management shake-up at medical equipment maker Convatec (CTEC) could be the start of a new way of thinking that could benefit investors, says AJ Bell. Convatec has poached Genus’ boss Karim Bitar to be its new chief executive to lead its turnaround effort just as the former is also losing its chairman and deputy chairman. ‘Convatec desperately needs a new lease of life as it has been a serial disappointment for most of its time as a listed business,’ said analyst Russ Mould. Last month, the group announced plans to invest $150 million over three years and Mould said ‘the scale of such investment was significantly greater than expected, despite having scope to deliver $120 million in annual savings by 2023, as well as improvements in revenue growth and profit margins’. |
Posted at 22/1/2019 10:08 by robow One of Peel Hunt's stock picks for 2019Convatec (CTEC) The depressed share price at medical products company Convatec has led to a rise in the dividend yield but the poor sentiment is unfounded. Analyst Amy Walker retained her ‘hold’ recommendation and target price of 170p on the stock. She said that ‘low visibility on earnings momentum has depressed the share price, leading to a rise in the dividend yield’ but even if the group misses her ‘conservative& Walker is not pessimistic about the outlook for the company, stating that the demand for the medical technology firm’s products were ‘unlikely to change materially from their mid-single digit market growth rates’. She added that the company can ‘support a stable to growing dividend’ but the most likely driver of volatility is the share price ‘which declined more than 30% on the most recent profit warning’. |
Posted at 30/10/2018 09:55 by philanderer Numis upgrades Convatec to ‘buy’Numis has upgraded medical technology company Convatec (CTEC) after an ‘unwarranted&r Analyst Paul Cuddon upgraded his recommendation from ‘hold’ to ‘buy’ with a target price of 220p on the shares, which jumped 5.6% to 155p yesterday. ‘We do not think the loss of a chief executive and the decline in infusion devices warranted a 35% fall in Convatec’s share price, especially when the broader chronic care business is maintaining consistent 2% quarterly growth,’ he said. ‘We see full-year 2018 results, details on the self-help strategy and full-year 2019 outlook as key catalysts. The company trades on 10x enterprise value/earnings and offering sector leading free cashflow yield and so we upgrade to “buy”.&r |
Posted at 15/10/2018 20:46 by cantrememberthis2 Despite the warning and its cautious stance on the stock, RBC said the share price reset has gone too far and highlighted the fact that Convatec is still a cash generative business with attractive qualities."We would remind investors that Convatec is still a highly cash generative business, and at the current share price is generating a free cash flow yield of over 7%, with a dividend yield of 3%," it said. "With the performance wanting we would hope all options are now on the table to maximise shareholder value." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
